A clinical study to compare the effect of two drugs - patala kshara in tilataila and trikantakadi guggulu in patients with Benign Prostatic Hyperplasia.
Phase 3
- Conditions
- Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms
- Registration Number
- CTRI/2024/02/062595
- Lead Sponsor
- Dr Subi N H
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
•Patients with LUTS secondary to BPH and diagnosed by Transabdominal Ultrasound.
•BPH with IPSS score minimum 5.
•Patients who are willing to provide written informed consent
Exclusion Criteria
•Known cases of Prostatitis, Carcinoma Prostate and those who have undergone any surgery for Prostate.
•Known cases with complications of BPH like acute urinary retention, haematuria, hydronephrosis and renal insufficiency.
•Known cases of stricture of urethra, congenital contracture of bladder neck and bladder polyps and diverticula.
•BPH patients with severe cardiac disease, uncontrolled diabetes mellitus and immuno-compromised.
•Those who are contraindicated for the internal use of kshara.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome– International Prostate Symptom Score (IPSS) and QOL will be assessed using <br/ ><br>validated questionnaire to quantify the reduction in LUTS .Timepoint: At baseline, 31st day and 61st day.
- Secondary Outcome Measures
Name Time Method Change in Post-Void Residual urine volume (PVR) & Prostate Volume (PV) will be assessed using Transabdominal Ultrasound.Timepoint: At baseline & after 60 days